IDEXX Laboratories reported strong growth in Q3/26, leading to an increased full-year revenue forecast of 10.1%-10.8%. Key segments like VetLab consumables and the CAG department saw revenue increases of 16.1% and 11.3%, respectively, reflecting the company's core strength. IDEXX continues to maintain pricing power, successfully passing on price hikes and offsetting inflation, which improved gross and operating margins by 100 and 80 basis points year over year. This margin expansion highlights the company's operational efficiency and robust business model.
IDEXX Laboratories shares are trading at USD 689.90 on Pluang as of Nov 04, 2026 20:51 WIB, up 2.66% for the day. This price sits closer to the 52-week high of USD 766.68 than the low of USD 504.70, indicating strong market confidence despite the stock's premium valuation. The market cap stands at $52.94 billion, reflecting substantial investor interest even as typical holding time on Pluang is 45 days with a slightly higher sell order activity at 56%.
IDEXX Laboratories reported strong Q3 results with 9.86% organic revenue growth, 13.4% operating income growth, and 17.9% EPS growth, exceeding market expectations. The company raised its full-year revenue and EPS guidance, driven by its best-in-clas...
IDEXX Laboratories surged 20.2% after reporting stronger-than-expected Q3 earnings and raising its full-year revenue and EPS guidance. The veterinary diagnostics company showed growth despite a weak market for vet visits, driven by recurring revenue ...
